Autologous Platelet-Rich Plasma (PRP)
Millions of people, including athletes and physically active individuals, enjoy sports as a way of life. Regular physical activity and daily movement, however, can lead to pain and musculoskeletal injuries that limit and hinder daily functioning.
More than 600 clinical studies registered on PubMed investigate the effectiveness of Platelet-Rich Plasma (PRP) therapy. This autologous treatment has been evaluated across various medical specialties including physical medicine and rehabilitation, sports medicine, orthopedics, regenerative and wound healing medicine, neurosurgery, dentistry, ophthalmology, as well as aesthetic, plastic, maxillofacial, and cardiovascular surgery.
Regen Lab developed RegenKit® technology as the optimal solution for obtaining autologous platelet-rich plasma from venous blood.
What is Platelet-Rich Plasma (PRP)?
PRP therapy offers a highly promising biological solution to accelerate the healing of tendon injuries, muscle strains, and early-stage osteoarthritis naturally and without associated risks.
Platelet-rich plasma is a concentration of human platelets in a small volume of plasma. Platelets act as carriers of growth factors (PDGF, TGF-β, IGF, EGF, VEGF), which stimulate the proliferation of fibroblasts, osteoblasts, and endothelial cells to promote and accelerate the healing of both hard and soft tissues (e.g., collagen, tendons, muscles, ligaments, bones, skin).
Platelets are cells well-known for their role in blood clotting. When activated in the body, they release healing proteins known as growth factors. These growth factors act synergistically to speed up tissue repair.
How is the Procedure Performed?
The procedure is as follows: a small quantity of blood (4–5 cc) is drawn from the patient—similar to a standard blood test—and placed into a specialized container. It is then centrifuged for 5 minutes to isolate the plasma containing the platelets.
The platelets are then activated using calcium chloride (DNA activator) to release their stored growth factors (PDGF, TGF-β, VEGF, EGF, FGF, IGF-1) through a process called degranulation.
The injection can also be performed under ultrasound guidance for maximum precision. Platelets continue producing and releasing growth factors for approximately the first 7 days following activation.